跳至主要内容
临床试验/NCT02389166
NCT02389166已完成不适用

Randomized Clinical Trial Comparing High Flow Oxygen Delivery System (Optiflow) With Oxygen Therapy Under High-concentration Mask on Oxygenation of Patients Who Receive Sequential Non-Invasive Ventilation (NIV) Sessions

University Hospital, Bordeaux16 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2015年6月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
95
试验地点
16
主要终点
Average of oxygenation differences measured as the delta between PaO2/FiO2ratio at the end of the first ans second NIV session and at the end of the first and second oxygen therapy session.

研究概览

简要总结

Background : Patient with hypoxemic respiratory failure treated with NIV receive between NIV session oxygen therapy. Gaz exchange disorder with a decrease of the ratio between Partial Pressure of Arterial Oxygen (PaO2) and Inspired Fraction of Oxygen (FIO2) are noticed when NIV is stopped at the end of the session du to alveolar derecruitment Optiflow is a high flow oxygen delivery system used a heated humidifier and heated breathing circuit. In observational studies, Optiflow increase oxygenation of patients with hypoxemic respiratory failure. Oxygenation is better than under high-concentration mask and work of breathing is reduced.

The aim of the study is to compare in acute hypoxemic respiratory failure, optiflow to oxygen therapy under high-concentration mask, on patients oxygenation between NIV sessions (measured as the difference between PaO2/FiO2 ratio at the beginning and at the end of the session), during the first two NIV sessions

Study design : Prospective, randomized, controlled, multicentric, open clinical trial with two groups:

  • control group with conventional clinical management, oxygen therapy and sequential used of NIV
  • Optiflow group with high flow oxygen delivery system, conventional clinical management and sequential used of NIV for a period of 36 hours at least.

Number of subjects: 100 (50 patients per group) patients admitted in intensive Care Unit for hypoxemic respiratory failure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient at least 18 years old
  • Patients affiliated to or benefiting of the French social welfare system
  • Patients with ARDS on previously healthy lung. Acute respiratory insufficiency, defined as the PaO2/FIO2 ratio less than 200 mm Hg associated with the presence of lung infiltrates on chest radiograph
  • Free and informed consent of patient
  • Hospitalized in one of involved ICU

排除标准

  • Existence of criteria for intubation.
  • Refusal to participate in the study.
  • Pregnancy
  • Patient under guardianship or trusteeship
  • Patients for whom a decision of non intubation has been decided.
  • Patients who have received one or several NIV session for ARDS before hospital admission
  • Home noninvasive ventilation
  • Tracheostomy
  • Hemodynamic instability
  • Hypercapnia (PaCO2>45 mm Hg).
  • left ventricular failure (cardiogenic pulmonary acute edema).
  • Ineffective coughing.
  • Recent gastric or oesophageal surgery
  • Severe ventricular rhythm disorder
  • High digestive haemorrhage
  • Lack of collaboration
  • Pernicious vomiting
  • Upper airway obstruction
  • Severe sepsis.
  • Undrained pneumothorax.

研究组 & 干预措施

Optiflow group

Experimental

干预措施: Optiflow (Device)

Control group

Active Comparator

干预措施: Conventional oxygen therapy (Device)

结局指标

主要结局

Average of oxygenation differences measured as the delta between PaO2/FiO2ratio at the end of the first ans second NIV session and at the end of the first and second oxygen therapy session.

时间窗: 28 days

Average of oxygenation differences measured as the delta between PaO2/FiO2 ratio at the end of the first NIV session and at the end of the first oxygen therapy session (according group of treatment) on the one hand and on the other hand the delta between PaO2/FiO2 ratio at the end of the second NIV session and at the end of the second oxygen thrapy session Five measurements of PaO2/FiO2 ratio are realized with arterial blood gases: * at the time of inclusion, * at the time of the end of first NIV session, * at the time of the end of first oxygen therapy session, or at the time of rescue NIV or at the time of réintubation * at the time of the end of second NIV session, * at the time of the end of second oxygen therapy session These five measurements are usually realised, and they are important to optimize patient management. The primary endpoint is based on these five measurements.

次要结局

  • Incidence of serious adverse events between the two NIV sessions(28 days)
  • incidence of intubation during the NIV treatment of Acute respiratory distress syndrome (ARDS)(28 days)
  • Respiratory rate between the two NIV sessions(28 days)
  • ICU mortality(28 days)
  • ICU length of stay(28 days)
  • 28 days survival(28 days)
  • Hospital mortality(28 days)
  • comfort score dyspnea beetween the two NIV sessions(28 days)
  • duration of mechanical ventilation(28 days)

研究者

发起方
University Hospital, Bordeaux
申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验